[go: up one dir, main page]

WO2004050834A3 - GPC99 AND GPC99a: METHODS AND COMPOSITIONS FOR TREATING CANCER - Google Patents

GPC99 AND GPC99a: METHODS AND COMPOSITIONS FOR TREATING CANCER Download PDF

Info

Publication number
WO2004050834A3
WO2004050834A3 PCT/US2003/037813 US0337813W WO2004050834A3 WO 2004050834 A3 WO2004050834 A3 WO 2004050834A3 US 0337813 W US0337813 W US 0337813W WO 2004050834 A3 WO2004050834 A3 WO 2004050834A3
Authority
WO
WIPO (PCT)
Prior art keywords
gpc99a
gpc99
compositions
methods
treating cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/037813
Other languages
French (fr)
Other versions
WO2004050834A2 (en
Inventor
Ronan C O'hagan
Karuppiah Kannan
Rijian Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aveo Pharmaceuticals Inc
Original Assignee
Genpath Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genpath Pharmaceuticals Inc filed Critical Genpath Pharmaceuticals Inc
Priority to AU2003298708A priority Critical patent/AU2003298708A1/en
Publication of WO2004050834A2 publication Critical patent/WO2004050834A2/en
Publication of WO2004050834A3 publication Critical patent/WO2004050834A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

This invention provides methods and compositions for treating hyperproliferative conditions such as cancer using reagents relating to the GPC99 or GPC99a gene.
PCT/US2003/037813 2002-11-27 2003-11-26 GPC99 AND GPC99a: METHODS AND COMPOSITIONS FOR TREATING CANCER Ceased WO2004050834A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003298708A AU2003298708A1 (en) 2002-11-27 2003-11-26 GPC99 AND GPC99a: METHODS AND COMPOSITIONS FOR TREATING CANCER

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42987702P 2002-11-27 2002-11-27
US60/429,877 2002-11-27

Publications (2)

Publication Number Publication Date
WO2004050834A2 WO2004050834A2 (en) 2004-06-17
WO2004050834A3 true WO2004050834A3 (en) 2004-12-02

Family

ID=32469383

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/037813 Ceased WO2004050834A2 (en) 2002-11-27 2003-11-26 GPC99 AND GPC99a: METHODS AND COMPOSITIONS FOR TREATING CANCER

Country Status (2)

Country Link
AU (1) AU2003298708A1 (en)
WO (1) WO2004050834A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0521139D0 (en) * 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
GB0708002D0 (en) * 2007-04-25 2007-06-06 Univ Sheffield Antibodies
JP5099856B2 (en) * 2007-11-26 2012-12-19 独立行政法人科学技術振興機構 Metabolic syndrome treatment or prevention agent, test method, test drug, and screening method for candidate compound of metabolic syndrome treatment drug
CA3075867A1 (en) * 2017-09-13 2019-03-21 Gene Techno Science Co., Ltd. Anti-ramp2 antibody
CN110075276A (en) * 2019-03-29 2019-08-02 中国人民解放军陆军军医大学第一附属医院 Application of the ADM competitive antagonist AMA in anti-glioma angiogenesis treatment
CN110090297B (en) * 2019-03-29 2021-05-14 中国人民解放军陆军军医大学第一附属医院 Use of ADM competitive antagonist AMA in glioma immunotherapy
GB202303531D0 (en) * 2023-03-10 2023-04-26 Fusion Antibodies Plc Antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033877A1 (en) * 1997-12-24 1999-07-08 Immunex Corporation V196 dna and polypeptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033877A1 (en) * 1997-12-24 1999-07-08 Immunex Corporation V196 dna and polypeptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FOORD S.M. ET AL: "RAMPs: accessory proteins for seven transmembrane domain receptors", TRENDS IN PHARMACOLOGIAL SCIENCE, vol. 20, May 1999 (1999-05-01), pages 184 - 187, XP004170237 *
MCLATCHIE L.M. ET AL: "RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor", NATURE, vol. 393, 1998, pages 333 - 339, XP002922193 *

Also Published As

Publication number Publication date
AU2003298708A8 (en) 2004-06-23
WO2004050834A2 (en) 2004-06-17
AU2003298708A1 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
WO2003008623A3 (en) Methylation analysis using nicking agents
WO2005027962A3 (en) 4’-thionucleosides and oligomeric compounds
WO2003066802A3 (en) Gene expression analysis using nicking agents
WO2005014850A3 (en) Systems and methods for analyzing nucleic acid sequences
EP2671581B8 (en) Compositions and methods for treating cancer
WO2004023092A3 (en) Genetic analysis and authentication
CA2651453C (en) 5'-modified bicyclic nucleic acid analogs
WO2007002204A3 (en) Pyrosequencing methods and related compostions
WO2004037988A3 (en) Methods for synthesizing complementary dna
WO2007059041A3 (en) Combinations and methods of using an immunomodulatory oligodeoxynucleotide
WO2004047760A3 (en) Novel chemical compounds
TW200500071A (en) Methods and reagents for treating infections of clostridium difficile and diseases associated therewith
WO2004080418A3 (en) Nucleic acid compounds for inhibiting angiogenesis and tumor growth
WO2008013589A3 (en) Treatment of ras-expressing tumors
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
WO2003099217A3 (en) Methods of treating bacterial infections and diseases associated therewith
WO2004044160A3 (en) Muc1 interference rna compositions and methods derived therefrom
WO2005009951A3 (en) Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use
WO2004087073A3 (en) Treatment of demyelinating conditions
WO2004058158A3 (en) Treatment of metastatic cancer with the b-subunit of shiga toxin
EP1551388A4 (en) Compounds useful for the treatment of cancer, compositions thereof and methods therewith
WO2005000207A3 (en) Pcdgf receptor antibodies and methods of use thereof
WO2004050834A3 (en) GPC99 AND GPC99a: METHODS AND COMPOSITIONS FOR TREATING CANCER
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
AU2003219160A1 (en) Methods and compositions for the treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP